Curie Institute

Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

Retrieved on: 
Martedì, Gennaio 30, 2024
SAN, Breast, University, International, MD Anderson Cancer Center, FACMG, FDA, VAF, Bone marrow, SVS, Cytogenetics, Genome, LRS, OGM, University of Toronto, TNBC, Pressure, Biomarker, PARP, Quality control, Karyotype, HRD, Saint John Regional Hospital, T-ALL, CRISPR, Curie Institute, Triple-negative breast cancer, In situ hybridization, FISH, Frog, Genomics, Hospital, HRP, Patient, Marfan syndrome, Fluorescence, NIST, DSM-IV codes, Doctor of Philosophy, Cancer, Multiple myeloma, Workflow, Gene editing, Research, KT, Cell, Down syndrome, NGS, Vaccine

During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.

Key Points: 
  • During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.
  • OGM is helping to unravel persistent, complex mysteries in genetic disease that impact people, even in more common disorders like Down syndrome and Marfan syndrome.
  • OGM has the potential to meet the key requirements of the cell and gene therapy community.
  • “I would encourage anyone who was unable to attend live to login, view these presentations and see how bright the future of cytogenetics is with OGM.”

Unpleasant Post Surgery Smells Are Common; Cinesteam® Can Help

Retrieved on: 
Mercoledì, Gennaio 3, 2024
Quality of life, Smell, Infection, Business, Research, Lead poisoning, Spice, Laboratory, Coffee, Patient, Curie Institute

FORT LAUDERDALE, Fla., Jan. 3, 2024 /PRNewswire/ -- There are many factors to consider during post-surgery recovery. One of those is unexpected or unpleasant smells coming from a healing wound. Often referred to as malodorous wounds, this kind of smell is common and can come from a variety of causes, such as necrotic tissue, an infection, or even a chemical reaction between a primary dressing and wound exudate.

Key Points: 
  • FORT LAUDERDALE, Fla., Jan. 3, 2024 /PRNewswire/ -- There are many factors to consider during post-surgery recovery.
  • One of those is unexpected or unpleasant smells coming from a healing wound.
  • In the end, the group found that cinnamon was by far the most effective and safe option for adsorbing unpleasant smells.
  • It is an ideal solution for those looking to improve their quality of life as they deal with malodorous wound smells in addition to the other challenges of surgery recovery.

These worms have rhythm

Retrieved on: 
Mercoledì, Dicembre 27, 2023
Cold Spring Harbor Laboratory, CSHL, Music, Protein, Mir-17 microRNA precursor family, SPRING, HHMI, Human, Brain, Pulse, Calculus, Cancer, Animal, Behavior, Gene expression, Curie Institute, Hammel (surname)

COLD SPRING HARBOR, N.Y., Dec. 27, 2023 /PRNewswire/ -- There's a rhythm to developing life.

Key Points: 
  • COLD SPRING HARBOR, N.Y., Dec. 27, 2023 /PRNewswire/ -- There's a rhythm to developing life.
  • Losing the rhythm can lead to diseases like cancer.
  • Cold Spring Harbor Laboratory (CSHL) Professor Christopher Hammell has found that in the worm C. elegans, this genetic orchestra has no single conductor.
  • Understanding how the worm's clock is regulated could help explain how time affects development in other animals.

IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate

Retrieved on: 
Martedì, Novembre 28, 2023
Safety, Treatment, Patient safety, Freezing, Teaching hospital, Patient, University of Montpellier, Neoplasm, Success, University, Kidney, MES, Urology, Physician, Quality of life, Curie Institute, Medical imaging, Pharmaceutical industry, Cancer, Study

ProSense® is approved for the treatment of benign and malignant kidney tumors in the U.S., Europe, and numerous other countries.

Key Points: 
  • ProSense® is approved for the treatment of benign and malignant kidney tumors in the U.S., Europe, and numerous other countries.
  • The causes of partial tumor response and persistent tumor residue after a T1a renal cryoablation procedure were assessed.
  • "The authors' findings are similar to the interim results from our own ICESECRET study in small renal masses which demonstrated an 89.5% recurrence-free rate.
  • We expect ICESECRET's five-year patient follow-up to be completed in 2026, with topline results available shortly afterwards."

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers

Retrieved on: 
Mercoledì, Novembre 2, 2022
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Marketing, PFS, Vaccination, HPV-positive oropharyngeal cancer, Avelumab, Progression-free survival, Department, Human, Curie Institute, RECIST, Risk, NEC, Doctor of Philosophy, TME, NYSE, Merck Group, PFE, Immunotherapy, Immune system, Cell, HPV, Safety, MVA, TNG, Pfizer, Patient, Neoplasm, Artificial intelligence, Gene, ESMO, Transgene, SITC, Cancer, Liver disease, Phase, HPV16, HIV disease progression rates, AMF, AstraZeneca, Drug development, Potyvirus, Tumor microenvironment, PD-L1, Curie Institute (Paris), Principal, E7, DCR, Precision medicine, Forward-looking statement, ORR, Vaccine, Pharmaceutical industry, Euronext

The trial is being conducted in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE), which are providing avelumab for the trial.

Key Points: 
  • The trial is being conducted in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE), which are providing avelumab for the trial.
  • Avelumab is co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer Inc. Transgene will continue to be the sponsor of the trial and conduct the trial.
  • Avelumab is not approved alone or in combination for the treatment of HPV16-positive anogenital tumors in any region.
  • The combination of TG4001 and avelumab demonstrated anti-tumor activity (22% ORR) in patients with previously treated recurrent and/or metastatic HPV-related cancers (including patients with oropharyngeal cancers and anogenital cancers).

DGAP-News: Defence Therapeutics Inc.:  DEFENCE’S ACCUMTM WITH ANTIBODY DRUG CONJUGATES (ADC) IN DEVELOPMENT AGAINST CANCER

Retrieved on: 
Martedì, Luglio 5, 2022
Cell, Mouse, FDA, Institute, ROS, IRCM, Patient, ADC, Curie Institute, HUS, Control, CEO, Breast cancer, Engineering, Cancer, Company, CSE, Toxicology, Catastrophic illness, Infection, Woman, Therapeutic index, CAGR, Radiation, Technology, News, Toxicity, DGAP, Radiopharmaceutical, Immunotherapy, Vaccine, Therapy, Forward-looking statement, Security (finance), Pharmaceutical industry, PDX, BC, Defense

Vancouver, BC, Canada, July 5th, 2022 - Defence Therapeutics Inc. (Defence or the Company), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to provide an update on its ADC programs in development using Defences AccumTM, including key in vivo studies with worldwide collaborators.

Key Points: 
  • Vancouver, BC, Canada, July 5th, 2022 - Defence Therapeutics Inc. (Defence or the Company), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to provide an update on its ADC programs in development using Defences AccumTM, including key in vivo studies with worldwide collaborators.
  • It will be immediately followed by a head-to-head toxicology and pharmacokinetic profile comparisons study of T-DM1 versus AccumTM T-DM1 in mice.
  • This study is to prove that the current treatment may be optimized using Defences AccumTM technology to enhance the drug delivery to the tumor cells.
  • "Defences AccumTM platform has been primarily developed and tested in vitro and in vivo to enhance the intranuclear drug delivery on multiple FDA approved antibody-conjugates or new conjugates under development.

European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

Retrieved on: 
Lunedì, Aprile 4, 2022
Population, Dacarbazine, The New England Journal of Medicine, Clinical trial, CHMP, Autoimmunity, Caregiver, Adult, European Commission, CRS, European Directive on Traditional Herbal Medicinal Products, Survival, Committee for Medicinal Products for Human Use, Cancer, TCR, EC, OS, Fever, Royal commission, Ipilimumab, Hope, Committee, Itch, Curie Institute, Nasdaq, Rash, Patient, Pembrolizumab, Infection, Pharmaceutical industry, Mum, Immunocore

KIMMTRAK, a bispecific T-cell engager, is the first therapy to demonstrate a survival benefit in patients with unresectable or metastatic uveal melanoma.

Key Points: 
  • KIMMTRAK, a bispecific T-cell engager, is the first therapy to demonstrate a survival benefit in patients with unresectable or metastatic uveal melanoma.
  • Data from the trial, the largest Phase 3 trial undertaken in mUM, showed that KIMMTRAK demonstrated unprecedented median OS benefit as a first-line treatment.
  • KIMMTRAK represents a paradigm shift in the treatment of unresectable or metastatic uveal melanoma.
  • Unresectable or metastatic uveal melanoma typically has a poor prognosis and had no approved treatment until KIMMTRAK.

DGAP-News: DEFENCE THERAPEUTICS: AN ANTI-CANCER SOLUTIONS PLATFORM COMPANY ADVANCING ITS VERSATILE ACCUM TECHNOLOGY

Retrieved on: 
Venerdì, Aprile 1, 2022
Company, Cancer, PDX, Therapy, Cell, University, E6, Ministry of Education (Malaysia), Forward-looking statement, Fortis Healthcare, ADC, ATF, GLP, News, Vaccine, DGAP, Research, Accum, Program, University of Birmingham, E7, EU, Documentation, Control, Dendritic cell, Technology, MHRA, Cervical cancer, Melanoma, Infection, Catastrophic illness, Animal, Curie Institute, Curie Institute (Paris), Breast cancer, Engineering, Health Canada, CSE, Security (finance), Dietary supplement, Pharmaceutical industry, BC, Defense

Defence is also advancing, at a fast pace, its ADC program against breast cancer.

Key Points: 
  • Defence is also advancing, at a fast pace, its ADC program against breast cancer.
  • Defence's lead ADC will be then tested under GLP standards prior to initiate a Phase I Trial against breast cancer.
  • "Defence Therapeutics is well position to prevent cancer with his versatile technology: a solution looking for a cancer to prevent and to treat.
  • The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.

DGAP-News: DEFENCE THERAPEUTICS SIGNS A COLLABORATION AGREEMENT WITH THE CURIE INSTITUTE FOR TESTING THE ACCUM-T-DM1 ADC THERAPEUTIC IN PDX MODELS OF BREAST CANCER

Retrieved on: 
Martedì, Giugno 29, 2021
Cancer, Cancer research, Patient derived xenograft, Xenotransplantation, Trastuzumab emtansine, Clinical medicine, PDX, Medical specialties, Breast cancer, Curie Institute

Vancouver, BC, Canada, June 29th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), is pleased to announce the establishment of a collaboration with the Curie Institute (Paris, France) to evaluate the therapeutic efficacy of Accum-T-DM1 ADC in patient-derived xenograft (PDX) models of breast cancer.

Key Points: 
  • Vancouver, BC, Canada, June 29th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), is pleased to announce the establishment of a collaboration with the Curie Institute (Paris, France) to evaluate the therapeutic efficacy of Accum-T-DM1 ADC in patient-derived xenograft (PDX) models of breast cancer.
  • Their scientific team has a wide expertise in the field of medical and experimental pharmacology with PDX models of cancer.
  • The agreement between the Curie Institute and Defence Therapeutics stipulates the following objectives related to the breast cancer:
    To perform a head-to-head toxicology profile comparisons of T-DM1 versus Accum-T-DM1 in mice.
  • Conduct a complete breast cancer efficacy study on PDX mice undergoing the ADC therapy, including in 3 HER2+ and in 1 triple-negative PDX.

Prestigious French cancer center Institut Curie digitizes pathology with solution from Sectra

Retrieved on: 
Mercoledì, Maggio 19, 2021
Curie Institute, Pathology, Digital pathology, Radium, Physical sciences, Natural sciences, Academic disciplines

b'LINKPING, Sweden, May 19, 2021 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will install its solution for digital pathology at Institut Curie, one of the most recognized and prestigious cancer centers in France.

Key Points: 
  • b'LINKPING, Sweden, May 19, 2021 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will install its solution for digital pathology at Institut Curie, one of the most recognized and prestigious cancer centers in France.
  • Institut Curie has become the third French healthcare provider to order Sectra\'s digital pathology solution within a four-month period, following previous orders from Institut Bergoni and GHU Paris psychiatrie & neurosciences.
  • The contract was signed in March 2021.\nSectra\'s pathology solution is part of its enterprise imaging solution.
  • For more information, visit sectra.com .\nInstitut Curie, France\'s leading cancer center, combines an internationally-renowned research center with a cutting-edge hospital group that treats all types of cancer, including the rarest.